secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cabaletta Bio, Inc. (CABA)
CIK:        0001759138
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0001193125-23-270840
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cabaletta Bio receives FDA clearance for fourth CABA-201 IND, now in generalized myasthenia gravis
--------------------------------------------------------------------------------

- FDA cleared IND for CABA-201 in generalized MG; fourth IND across autoimmune diseases.
- Phase 1/2 trial to enroll 12 patients in two parallel cohorts: AChR+ (n=6) and AChR- (n=6).
- Starting dose remains 1 x 10^6 cells/kg, consistent with lupus, myositis, and systemic sclerosis trials.
- gMG affects ~85% of an estimated 50,000-80,000 MG patients in the U.S.
- Company expects initial clinical data from lupus/myositis trials in H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759138/000119312523270840/0001193125-23-270840-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759138/000119312523270840/d854062d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-270840

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer